Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma

Current Cancer Drug Targets

Volumn 12, Issue 7, 2012, Pages 776-796

  Neri, Paola ^a,b   Bahlis, Nizar J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Southern Alberta Cancer Research Institute (SACRI)   (Canada)

Author keywords

Adhesion; Anti adhesion agents; CAM DR; Integrins; Microenvironment; Multiple myeloma

Indexed keywords

ALPHA INTEGRIN; BETA1 INTEGRIN; BETA2 INTEGRIN; BETA3 INTEGRIN; BETA7 INTEGRIN; BIVATUZUMAB; BORTEZOMIB; CAVEOLIN; CD31 ANTIGEN; CELL ADHESION MOLECULE; COLLAGEN; DEFIBROTIDE; ELOTUZUMAB; FIBRONECTIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LAMININ; LENALIDOMIDE; NATALIZUMAB; OSTEOPONTIN; SYNDECAN 1; THALIDOMIDE; UNINDEXED DRUG; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN;

APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW CELL; CELL CYCLE PROGRESSION; CELL MIGRATION; GENE ACTIVATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOBLAST; OSTEOCLAST; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MARROW; CELL ADHESION; CELL ADHESION MOLECULES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION;

EID: 84866373814     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912802429337     Document Type: Article

References (234)

1. Kyle, R. A.; Rajkumar, S. V. Monoclonal gammopathy of undetermined significance. Br. J. Haematol. 2006, 134 (6), 573-589.
2. Hideshima, T.; Chauhan, D.; Shima, Y.; Raje, N.; Davies, F. E.; Tai, Y. T.; Treon, S. P.; Lin, B.; Schlossman, R. L.; Richardson, P.; Muller, G.; Stirling, D. I.; Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96 (9), 2943-2950.
3. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V. J.; Elliott, P. J.; Adams, J.; Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61 (7), 3071-3076.
4. Richardson, P. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Seminars in Hematology 2005, 42 (4 Suppl 4), S9-15.
5. Kyle, R. A.; Rajkumar, S. V. Multiple myeloma. New Eng. J. Med. 2004, 351 (18), 1860-1873.
6. Elnenaei, M. O.; Gruszka-Westwood, A. M.; A'Hernt, R.; Matutes, E.; Sirohi, B.; Powles, R.; Catovsky, D. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica 2003, 88 (5), 529-537.
7. Tassone, P.; Tagliaferri, P.; Rossi, M.; Gaspari, M.; Terracciano, R.; Venuta, S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur. J. Cancer 2006, 42 (11), 1530-1538.
8. Damiano, J. S.; Cress, A. E.; Hazlehurst, L. A.; Shtil, A. A.; Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93 (5), 1658-1667.
9. Hideshima, T.; Podar, K.; Chauhan, D.; Anderson, K. C. Cytokines and signal transduction. Best Practice & Research 2005, 18 (4), 509-524.
10. Hideshima, T.; Mitsiades, C.; Tonon, G.; Richardson, P. G.; Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. 2007, 7 (8), 585-598.
11. Mitsiades, C. S.; Mitsiades, N. S.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 2006, 42 (11), 1564-1573.
12. Schaller, M. D. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim. Biophys. Acta 2001, 1540 (1), 1-21.
13. Teoh, G.; Anderson, K. C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematology/Oncology Clinics of North America 1997, 11 (1), 27-42.
14. Schlaepfer, D. D.; Hunter, T. Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol. 1998, 8 (4), 151-157.
15. Dedhar, S.; Williams, B.; Hannigan, G. Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol. 1999, 9 (8), 319-323.
16. Dolfi, F.; Garcia-Guzman, M.; Ojaniemi, M.; Nakamura, H.; Matsuda, M.; Vuori, K. The adaptor protein Crk connects multiple cellular stimuli to the JNK signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 1998, 95 (26), 15394-15399.
17. Aplin, A. E.; Howe, A. K.; Juliano, R. L. Cell adhesion molecules, signal transduction and cell growth. Curr. Opin. Cell Biol. 1999, 11 (6), 737-744.
18. Schwartz, M. A.; Assoian, R. K. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J. Cell Sci. 2001, 114 (Pt 14), 2553-2560.
19. Van Riet, I.; De Waele, M.; Remels, L.; Lacor, P.; Schots, R.; Van Camp, B. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br. J. Haematol. 1991, 79 (3), 421-427.
20. Uchiyama, H.; Barut, B. A.; Chauhan, D.; Cannistra, S. A.; Anderson, K. C. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992, 80 (9), 2306-2314.
21. Uchiyama, H.; Barut, B. A.; Mohrbacher, A. F.; Chauhan, D.; Anderson, K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82 (12), 3712-3720.
22. Kibler, C.; Schermutzki, F.; Waller, H. D.; Timpl, R.; Muller, C. A.; Klein, G. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes. Commun. 1998, 5 (4), 307-323.
23. Azab, A. K.; Azab, F.; Blotta, S.; Pitsillides, C. M.; Thompson, B.; Runnels, J. M.; Roccaro, A. M.; Ngo, H. T.; Melhem, M. R.; Sacco, A.; Jia, X.; Anderson, K. C.; Lin, C. P.; Rollins, B. J.; Ghobrial, I. M. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009, 114 (3), 619-629.
24. Podar, K.; Tai, Y. T.; Lin, B. K.; Narsimhan, R. P.; Sattler, M.; Kijima, T.; Salgia, R.; Gupta, D.; Chauhan, D.; Anderson, K. C. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J. Biol. Chem. 2002, 277 (10), 7875-7881.
25. Cerf-Bensussan, N.; Jarry, A.; Brousse, N.; Lisowska-Grospierre, B.; Guy-Grand, D.; Griscelli, C. A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes. Eur. J. Immunol. 1987, 17 (9), 1279-1285.
26. Tiisala, S.; Paavonen, T.; Renkonen, R. Alpha E beta 7 and alpha 4 beta 7 integrins associated with intraepithelial and mucosal homing, are expressed on macrophages. Eur. J. Immunol. 1995, 25 (2), 411-417.
27. Pellat-Deceunynck, C.; Barille, S.; Puthier, D.; Rapp, M. J.; Harousseau, J. L.; Bataille, R.; Amiot, M. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res. 1995, 55 (16), 3647-3653.
28. Kawano, M. M.; Mahmoud, M. S.; Huang, N.; Lisukov, I. A.; Mihara, K.; Tsujimoto, T.; Kuramoto, A. High proportions of VLA-5- immature myeloma cells correlated well with poor response to treatment in multiple myeloma. Br. J. Haematol. 1995, 91 (4), 860-864.
29. Jensen, G. S.; Belch, A. R.; Mant, M. J.; Ruether, B. A.; Yacyshyn, B. R.; Pilarski, L. M. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am. J. Hematol. 1993, 43 (1), 29-36.
30. Pulido, R.; Elices, M. J.; Campanero, M. R.; Osborn, L.; Schiffer, S.; Garcia-Pardo, A.; Lobb, R.; Hemler, M. E.; Sanchez-Madrid, F. Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha 4 epitopes. J. Biol. Chem. 1991, 266 (16), 10241-10245.
31. Elices, M. J.; Osborn, L.; Takada, Y.; Crouse, C.; Luhowskyj, S.; Hemler, M. E.; Lobb, R. R. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990, 60 (4), 577-584.
32. Shain, K. H.; Yarde, D. N.; Meads, M. B.; Huang, M.; Jove, R.; Hazlehurst, L. A.; Dalton, W. S. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009, 69 (3), 1009-1015.
33. Tai, Y. T.; Podar, K.; Catley, L.; Tseng, Y. H.; Akiyama, M.; Shringarpure, R.; Burger, R.; Hideshima, T.; Chauhan, D.; Mitsiades, N.; Richardson, P.; Munshi, N. C.; Kahn, C. R.; Mitsiades, C.; Anderson, K. C. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003, 63 (18), 5850-5858.
34. Holt, R. U.; Baykov, V.; Ro, T. B.; Brabrand, S.; Waage, A.; Sundan, A.; Borset, M. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 2005, 90 (4), 479-488.
35. Sanz-Rodriguez, F.; Hidalgo, A.; Teixido, J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001, 97 (2), 346-351.
36. Azab, A. K.; Runnels, J. M.; Pitsillides, C.; Moreau, A. S.; Azab, F.; Leleu, X.; Jia, X.; Wright, R.; Ospina, B.; Carlson, A. L.; Alt, C.; Burwick, N.; Roccaro, A. M.; Ngo, H. T.; Farag, M.; Melhem, M. R.; Sacco, A.; Munshi, N. C.; Hideshima, T.; Rollins, B. J.; Anderson, K. C.; Kung, A. L.; Lin, C. P.; Ghobrial, I. M. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113 (18), 4341-4351.
37. Shain, K. H.; Landowski, T. H.; Dalton, W. S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 2002, 168 (5), 2544-2553.
38. Landowski, T. H.; Olashaw, N. E.; Agrawal, D.; Dalton, W. S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003, 22 (16), 2417-2421.
39. Butcher, E. C.; Williams, M.; Youngman, K.; Rott, L.; Briskin, M. Lymphocyte trafficking and regional immunity. Adv. Immunol. 1999, 72, 209-253.
40. Binion, D. G.; West, G. A.; Ina, K.; Ziats, N. P.; Emancipator, S. N.; Fiocchi, C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997, 112 (6), 1895-1907.
41. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110 (6), 673-687.
42. Hurt, E. M.; Wiestner, A.; Rosenwald, A.; Shaffer, A. L.; Campo, E.; Grogan, T.; Bergsagel, P. L.; Kuehl, W. M.; Staudt, L. M. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004, 5 (2), 191-199.
43. Moreaux, J.; Hose, D.; Jourdan, M.; Reme, T.; Hundemer, M.; Moos, M.; Robert, N.; Moine, P.; De Vos, J.; Goldschmidt, H.; Klein, B. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 2007, 92 (6), 803-811.
44. Zhan, F.; Huang, Y.; Colla, S.; Stewart, J. P.; Hanamura, I.; Gupta, S.; Epstein, J.; Yaccoby, S.; Sawyer, J.; Burington, B.; Anaissie, E.; Hollmig, K.; Pineda-Roman, M.; Tricot, G.; van Rhee, F.; Walker, R.; Zangari, M.; Crowley, J.; Barlogie, B.; Shaughnessy, J. D., Jr. The molecular classification of multiple myeloma. Blood 2006, 108 (6), 2020-2028.
45. Bergsagel, P. L.; Kuehl, W. M.; Zhan, F.; Sawyer, J.; Barlogie, B.; Shaughnessy, J., Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106 (1), 296-303.
46. Neri, P.; Ren, L.; Azab, A. K.; Brentnall, M.; Gratton, K.; Klimowicz, A. C.; Lin, C.; Duggan, P.; Tassone, P.; Mansoor, A.; Stewart, D. A.; Boise, L. H.; Ghobrial, I. M.; Bahlis, N. J. Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 2011, 117 (23), 6202-6213.
47. Tatsumi, T.; Shimazaki, C.; Goto, H.; Araki, S.; Sudo, Y.; Yamagata, N.; Ashihara, E.; Inaba, T.; Fujita, N.; Nakagawa, M. Expression of adhesion molecules on myeloma cells. Jpn. J. Cancer Res. 1996, 87 (8), 837-842.
48. Smith, A.; Stanley, P.; Jones, K.; Svensson, L.; McDowall, A.; Hogg, N. The role of the integrin LFA-1 in T-lymphocyte migration. Immunol. Rev. 2007, 218, 135-146.
49. Vacca, A.; Di Loreto, M.; Ribatti, D.; Di Stefano, R.; Gadaleta-Caldarola, G.; Iodice, G.; Caloro, D.; Dammacco, F. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am. J. Hematol. 1995, 50 (1), 9-14.
50. Schmidmaier, R.; Morsdorf, K.; Baumann, P.; Emmerich, B.; Meinhardt, G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. The International Journal of Biological Markers 2006, 21 (4), 218-222.
51. Asosingh, K.; Vankerkhove, V.; Van Riet, I.; Van Camp, B.; Vanderkerken, K. Selective in vivo growth of lymphocyte functionassociated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion. Exp. Hematol. 2003, 31 (1), 48-55.
52. Caers, J.; Gunthert, U.; De Raeve, H.; Van Valckenborgh, E.; Menu, E.; Van Riet, I.; Van Camp, B.; Vanderkerken, K. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br. J. Haematol. 2006, 132 (4), 469-477.
53. Abe, M.; Hiura, K.; Wilde, J.; Shioyasono, A.; Moriyama, K.; Hashimoto, T.; Kido, S.; Oshima, T.; Shibata, H.; Ozaki, S.; Inoue, D.; Matsumoto, T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104 (8), 2484-2491.
54. Ria, R.; Vacca, A.; Ribatti, D.; Di Raimondo, F.; Merchionne, F.; Dammacco, F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002, 87 (8), 836-845.
55. Wight, T. N.; Kinsella, M. G.; Keating, A.; Singer, J. W. Proteoglycans in human long-term bone marrow cultures: biochemical and ultrastructural analyses. Blood 1986, 67 (5), 1333-1343.
56. Itano, N.; Atsumi, F.; Sawai, T.; Yamada, Y.; Miyaishi, O.; Senga, T.; Hamaguchi, M.; Kimata, K. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proceedings of the National Academy of Sciences of the United States of America 2002, 99 (6), 3609-3614.
57. Dahl, I. M.; Turesson, I.; Holmberg, E.; Lilja, K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood 1999, 93 (12), 4144-4148.
58. Adamia, S.; Reiman, T.; Crainie, M.; Mant, M. J.; Belch, A. R.; Pilarski, L. M. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood 2005, 105 (12), 4836-4844.
59. Naor, D.; Nedvetzki, S.; Golan, I.; Melnik, L.; Faitelson, Y. CD44 in cancer. Cr. Rev. Cl. Lab. Sc. 2002, 39 (6), 527-579.
60. Stauder, R.; Van Driel, M.; Schwarzler, C.; Thaler, J.; Lokhorst, H. M.; Kreuser, E. D.; Bloem, A. C.; Gunthert, U.; Eisterer, W. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood 1996, 88 (8), 3101-3108.
61. Eisterer, W.; Bechter, O.; Hilbe, W.; van Driel, M.; Lokhorst, H. M.; Thaler, J.; Bloem, A. C.; Gunthert, U.; Stauder, R. CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma. Leukemia res. 2001, 25 (12), 1051-1057.
62. Liebisch, P.; Eppinger, S.; Schopflin, C.; Stehle, G.; Munzert, G.; Dohner, H.; Schmid, M. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 2005, 90 (4), 489-493.
63. Genty, V.; Dine, G.; Dufer, J. Phenotypical alterations induced by glucocorticoids resistance in RPMI 8226 human myeloma cells. Leukemia res. 2004, 28 (3), 307-313.
64. Ohwada, C.; Nakaseko, C.; Koizumi, M.; Takeuchi, M.; Ozawa, S.; Naito, M.; Tanaka, H.; Oda, K.; Cho, R.; Nishimura, M.; Saito, Y. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur. J. Haematol. 2008, 80 (3), 245-250.
65. Turley, E. A.; Belch, A. J.; Poppema, S.; Pilarski, L. M. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood 1993, 81 (2), 446-453.
66. Crainie, M.; Belch, A. R.; Mant, M. J.; Pilarski, L. M. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 1999, 93 (5), 1684-1696.
67. Mohapatra, S.; Yang, X.; Wright, J. A.; Turley, E. A.; Greenberg, A. H. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J. Exp. Med. 1996, 183 (4), 1663-1668.
68. Hall, C. L.; Wang, C.; Lange, L. A.; Turley, E. A. Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. J. Cell Biol. 1994, 126 (2), 575-588.
69. Masellis-Smith, A.; Belch, A. R.; Mant, M. J.; Turley, E. A.; Pilarski, L. M. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood 1996, 87 (5), 1891-1899.
70. Maxwell, C. A.; Keats, J. J.; Belch, A. R.; Pilarski, L. M.; Reiman, T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res. 2005, 65 (3), 850-860.
71. Deaglio, S.; Mehta, K.; Malavasi, F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leukemia res. 2001, 25 (1), 1-12.
72. Lin, P.; Owens, R.; Tricot, G.; Wilson, C. S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 2004, 121 (4), 482-488.
73. Deaglio, S.; Morra, M.; Mallone, R.; Ausiello, C. M.; Prager, E.; Garbarino, G.; Dianzani, U.; Stockinger, H.; Malavasi, F. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J. Immunol. 1998, 160 (1), 395-402.
74. Newman, P. J. The biology of PECAM-1. J. Clin. Invest. 1997, 99 (1), 3-8.
75. Vallario, A.; Chilosi, M.; Adami, F.; Montagna, L.; Deaglio, S.; Malavasi, F.; Caligaris-Cappio, F. Human myeloma cells express the CD38 ligand CD31. Br. J. Haematol. 1999, 105 (2), 441-444.
76. Bernfield, M.; Gotte, M.; Park, P. W.; Reizes, O.; Fitzgerald, M. L.; Lincecum, J.; Zako, M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68 729-777.
77. Woods, A.; Couchman, J. R. Syndecans: synergistic activators of cell adhesion. Trends Cell Biol. 1998, 8 (5), 189-192.
78. Sanderson, R. D.; Lalor, P.; Bernfield, M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989, 1 (1), 27-35.
79. Ridley, R. C.; Xiao, H.; Hata, H.; Woodliff, J.; Epstein, J.; Sanderson, R. D. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993, 81 (3), 767-774.
80. Purushothaman, A.; Uyama, T.; Kobayashi, F.; Yamada, S.; Sugahara, K.; Rapraeger, A. C.; Sanderson, R. D. Heparanaseenhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115 (12), 2449-2457.
81. Dhodapkar, M. V.; Kelly, T.; Theus, A.; Athota, A. B.; Barlogie, B.; Sanderson, R. D. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br. J. Haematol. 1997, 99 (2), 368-371.
82. Seidel, C.; Sundan, A.; Hjorth, M.; Turesson, I.; Dahl, I. M.; Abildgaard, N.; Waage, A.; Borset, M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000, 95 (2), 388-392.
83. Berger, L. C.; Hawley, T. S.; Lust, J. A.; Goldman, S. J.; Hawley, R. G. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem. Bioph. Res. Co.1994, 202 (1), 596-605.
84. Ogata, A.; Chauhan, D.; Urashima, M.; Teoh, G.; Treon, S. P.; Anderson, K. C. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin. Cancer Res. 1997, 3 (6), 1017-1022.
85. Hideshima, T.; Nakamura, N.; Chauhan, D.; Anderson, K. C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20 (42), 5991-6000.
86. Chauhan, D.; Pandey, P.; Hideshima, T.; Treon, S.; Raje, N.; Davies, F. E.; Shima, Y.; Tai, Y. T.; Rosen, S.; Avraham, S.; Kharbanda, S.; Anderson, K. C. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem. 2000, 275 (36), 27845-27850.
87. Urashima, M.; Teoh, G.; Chauhan, D.; Hoshi, Y.; Ogata, A.; Treon, S. P.; Schlossman, R. L.; Anderson, K. C. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997, 90 (1), 279-289.
88. Vincent, T.; Mechti, N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004, 18 (5), 967-975.
89. Lowik, C. W.; van der Pluijm, G.; Bloys, H.; Hoekman, K.; Bijvoet, O. L.; Aarden, L. A.; Papapoulos, S. E. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem. Bioph. Res. Co. 1989, 162 (3), 1546-1552.
90. Tanaka, Y.; Abe, M.; Hiasa, M.; Oda, A.; Amou, H.; Nakano, A.; Takeuchi, K.; Kitazoe, K.; Kido, S.; Inoue, D.; Moriyama, K.; Hashimoto, T.; Ozaki, S.; Matsumoto, T. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin. Cancer Res. 2007, 13 (3), 816-823.
91. Sehgal, P. B. Interleukin-6: molecular pathophysiology. J. Invest. Dermatol. 1990, 94 (6 Suppl), 2S-6S.
92. Tassone, P.; Neri, P.; Burger, R.; Savino, R.; Shammas, M.; Catley, L.; Podar, K.; Chauhan, D.; Masciari, S.; Gozzini, A.; Tagliaferri, P.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin. Cancer Res. 2005, 11 (11), 4251-4258.
93. Abboud, S. L.; Bethel, C. R.; Aron, D. C. Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells. J. Clin. Invest. 1991, 88 (2), 470-475.
94. Jelinek, D. F.; Witzig, T. E.; Arendt, B. K. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J. Immunol. 1997, 159 (1), 487-496.
95. Ferlin, M.; Noraz, N.; Hertogh, C.; Brochier, J.; Taylor, N.; Klein, B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br. J. Haematol. 2000, 111 (2), 626-634.
96. Qiang, Y. W.; Kopantzev, E.; Rudikoff, S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002, 99 (11), 4138-4146.
97. Georgii-Hemming, P.; Wiklund, H. J.; Ljunggren, O.; Nilsson, K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996, 88 (6), 2250-2258.
98. Ogawa, M.; Nishiura, T.; Oritani, K.; Yoshida, H.; Yoshimura, M.; Okajima, Y.; Ishikawa, J.; Hashimoto, K.; Matsumura, I.; Tomiyama, Y.; Matsuzawa, Y. Cytokines prevent dexamethasoneinduced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. 2000, 60 (15), 4262-4269.
99. Mitsiades, C. S.; Mitsiades, N.; Poulaki, V.; Schlossman, R.; Akiyama, M.; Chauhan, D.; Hideshima, T.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. Activation of NFkappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21 (37), 5673-5683.
100. Menu, E.; Kooijman, R.; Van Valckenborgh, E.; Asosingh, K.; Bakkus, M.; Van Camp, B.; Vanderkerken, K. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Brit. J. Cancer 2004, 90 (5), 1076-1083.
101. Qiang, Y. W.; Yao, L.; Tosato, G.; Rudikoff, S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 2004, 103 (1), 301-308.
102. Mitsiades, C. S.; Mitsiades, N. S.; McMullan, C. J.; Poulaki, V.; Shringarpure, R.; Akiyama, M.; Hideshima, T.; Chauhan, D.; Joseph, M.; Libermann, T. A.; Garcia-Echeverria, C.; Pearson, M. A.; Hofmann, F.; Anderson, K. C.; Kung, A. L. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5 (3), 221-230.
103. Hargreaves, D. C.; Hyman, P. L.; Lu, T. T.; Ngo, V. N.; Bidgol, A.; Suzuki, G.; Zou, Y. R.; Littman, D. R.; Cyster, J. G. A coordinated change in chemokine responsiveness guides plasma cell movements. J. Exp. Med. 2001, 194 (1), 45-56.
104. Alsayed, Y.; Ngo, H.; Runnels, J.; Leleu, X.; Singha, U. K.; Pitsillides, C. M.; Spencer, J. A.; Kimlinger, T.; Ghobrial, J. M.; Jia, X.; Lu, G.; Timm, M.; Kumar, A.; Cote, D.; Veilleux, I.; Hedin, K. E.; Roodman, G. D.; Witzig, T. E.; Kung, A. L.; Hideshima, T.; Anderson, K. C.; Lin, C. P.; Ghobrial, I. M. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109 (7), 2708-2717.
105. Trentin, L.; Miorin, M.; Facco, M.; Baesso, I.; Carraro, S.; Cabrelle, A.; Maschio, N.; Bortoli, M.; Binotto, G.; Piazza, F.; Adami, F.; Zambello, R.; Agostini, C.; Semenzato, G. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br. J. Haematol. 2007, 138 (5), 594-602.
106. Kim, S. W.; Kim, H. Y.; Lee, H. J.; Yun, H. J.; Kim, S.; Jo, D. Y. Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells. Leukemia Lymphoma 2009, 50 (7), 1163-1173.
107. Martin, S. K.; Diamond, P.; Williams, S. A.; To, L. B.; Peet, D. J.; Fujii, N.; Gronthos, S.; Harris, A. L.; Zannettino, A. C. Hypoxiainducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 2010, 95 (5), 776-784.
108. Hideshima, T.; Chauhan, D.; Hayashi, T.; Podar, K.; Akiyama, M.; Gupta, D.; Richardson, P.; Munshi, N.; Anderson, K. C. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol. Cancer Ther. 2002, 1 (7), 539-544.
109. Parmo-Cabanas, M.; Bartolome, R. A.; Wright, N.; Hidalgo, A.; Drager, A. M.; Teixido, J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp. Cell Res. 2004, 294 (2), 571-580.
110. Parmo-Cabanas, M.; Molina-Ortiz, I.; Matias-Roman, S.; Garcia-Bernal, D.; Carvajal-Vergara, X.; Valle, I.; Pandiella, A.; Arroyo, A. G.; Teixido, J. Role of metalloproteinases MMP-9 and MT1- MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J. Pathol. 2006, 208 (1), 108-118.
111. Lu, Z. Y.; Zhang, X. G.; Rodriguez, C.; Wijdenes, J.; Gu, Z. J.; Morel-Fournier, B.; Harousseau, J. L.; Bataille, R.; Rossi, J. F.; Klein, B. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995, 85 (9), 2521-2527.
112. Tinhofer, I.; Marschitz, I.; Henn, T.; Egle, A.; Greil, R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000, 95 (2), 610-618.
113. Mackay, F.; Browning, J. L. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol. 2002, 2 (7), 465-475.
114. Gross, J. A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S. R.; Madden, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; Moore, M.; Littau, A.; Grossman, A.; Haugen, H.; Foley, K.; Blumberg, H.; Harrison, K.; Kindsvogel, W.; Clegg, C. H. TACI and BCMA are receptors for a TNF homologue implicated in Bcell autoimmune disease. Nature 2000, 404 (6781), 995-999.
115. Thompson, J. S.; Bixler, S. A.; Qian, F.; Vora, K.; Scott, M. L.; Cachero, T. G.; Hession, C.; Schneider, P.; Sizing, I. D.; Mullen, C.; Strauch, K.; Zafari, M.; Benjamin, C. D.; Tschopp, J.; Browning, J. L.; Ambrose, C. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (New York, N.Y.) 2001, 293 (5537), 2108-2111.
116. Moreaux, J.; Legouffe, E.; Jourdan, E.; Quittet, P.; Reme, T.; Lugagne, C.; Moine, P.; Rossi, J. F.; Klein, B.; Tarte, K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004, 103 (8), 3148-3157.
117. Novak, A. J.; Darce, J. R.; Arendt, B. K.; Harder, B.; Henderson, K.; Kindsvogel, W.; Gross, J. A.; Greipp, P. R.; Jelinek, D. F. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103 (2), 689-694.
118. Moreaux, J.; Cremer, F. W.; Reme, T.; Raab, M.; Mahtouk, K.; Kaukel, P.; Pantesco, V.; De Vos, J.; Jourdan, E.; Jauch, A.; Legouffe, E.; Moos, M.; Fiol, G.; Goldschmidt, H.; Rossi, J. F.; Hose, D.; Klein, B. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005, 106 (3), 1021-1030.
119. Tai, Y. T.; Li, X. F.; Breitkreutz, I.; Song, W.; Neri, P.; Catley, L.; Podar, K.; Hideshima, T.; Chauhan, D.; Raje, N.; Schlossman, R.; Richardson, P.; Munshi, N. C.; Anderson, K. C. Role of B-cellactivating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006, 66 (13), 6675-6682.
120. Neri, P.; Kumar, S.; Fulciniti, M. T.; Vallet, S.; Chhetri, S.; Mukherjee, S.; Tai, Y.; Chauhan, D.; Tassone, P.; Venuta, S.; Munshi, N. C.; Hideshima, T.; Anderson, K. C.; Raje, N. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 2007, 13 (19), 5903-5909.
121. Carter, A.; Merchav, S.; Silvian-Draxler, I.; Tatarsky, I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol. 1990, 74 (4), 424-431.
122. Hideshima, T.; Chauhan, D.; Schlossman, R.; Richardson, P.; Anderson, K. C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20 (33), 4519-4527.
123. Guo, D.; Dunbar, J. D.; Yang, C. H.; Pfeffer, L. M.; Donner, D. B. Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J. Immunol. 1998, 160 (6), 2742-2750.
124. Johrer, K.; Janke, K.; Krugmann, J.; Fiegl, M.; Greil, R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin. Cancer Res. 2004, 10 (6), 1901-1910.
125. Lichtenstein, A.; Berenson, J.; Norman, D.; Chang, M. P.; Carlile, A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989, 74 (4), 1266-1273.
126. Filella, X.; Blade, J.; Guillermo, A. L.; Molina, R.; Rozman, C.; Ballesta, A. M. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect. Prev. 1996, 20 (1), 52-56.
127. Blade, J.; Filella, X.; Montoto, S.; Bosch, F.; Rosinol, L.; Coca, F.; Gine, E.; Nadal, E.; Aymerich, M.; Rozman, M.; Montserrat, E. Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br. J. Haematol. 2002, 117 (2), 387-389.
128. Kumar, S.; Witzig, T. E.; Greipp, P. R.; Rajkumar, S. V. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. Br. J. Haematol. 2003, 122 (2), 272-274.
129. Kumar, S.; Witzig, T. E.; Timm, M.; Haug, J.; Wellik, L.; Fonseca, R.; Greipp, P. R.; Rajkumar, S. V. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003, 17 (10), 2025-2031.
130. Podar, K.; Tai, Y. T.; Davies, F. E.; Lentzsch, S.; Sattler, M.; Hideshima, T.; Lin, B. K.; Gupta, D.; Shima, Y.; Chauhan, D.; Mitsiades, C.; Raje, N.; Richardson, P.; Anderson, K. C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98 (2), 428-435.
131. Dankbar, B.; Padro, T.; Leo, R.; Feldmann, B.; Kropff, M.; Mesters, R. M.; Serve, H.; Berdel, W. E.; Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumorstromal cell interactions in multiple myeloma. Blood 2000, 95 (8), 2630-2636.
132. Podar, K.; Anderson, K. C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105 (4), 1383-1395.
133. Ribatti, D.; Vacca, A.; Nico, B.; Quondamatteo, F.; Ria, R.; Minischetti, M.; Marzullo, A.; Herken, R.; Roncali, L.; Dammacco, F. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Brit. J. Cancer 1999, 79 (3-4), 451-455.
134. Lin, B.; Podar, K.; Gupta, D.; Tai, Y. T.; Li, S.; Weller, E.; Hideshima, T.; Lentzsch, S.; Davies, F.; Li, C.; Weisberg, E.; Schlossman, R. L.; Richardson, P. G.; Griffin, J. D.; Wood, J.; Munshi, N. C.; Anderson, K. C. The vascular endothelial growthfactor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002, 62 (17), 5019-5026.
135. Podar, K.; Tonon, G.; Sattler, M.; Tai, Y. T.; Legouill, S.; Yasui, H.; Ishitsuka, K.; Kumar, S.; Kumar, R.; Pandite, L. N.; Hideshima, T.; Chauhan, D.; Anderson, K. C. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 2006, 103 (51), 19478-19483.
136. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4 (12), 915-925.
137. Iwasaki, T.; Hamano, T.; Ogata, A.; Hashimoto, N.; Kitano, M.; Kakishita, E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br. J. Haematol. 2002, 116 (4), 796-802.
138. Derksen, P. W.; Keehnen, R. M.; Evers, L. M.; van Oers, M. H.; Spaargaren, M.; Pals, S. T. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002, 99 (4), 1405-1410.
139. Holt, R. U.; Fagerli, U. M.; Baykov, V.; Ro, T. B.; Hov, H.; Waage, A.; Sundan, A.; Borset, M. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 2008, 93 (4), 619-622.
140. Standal, T.; Abildgaard, N.; Fagerli, U. M.; Stordal, B.; Hjertner, O.; Borset, M.; Sundan, A. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007, 109 (7), 3024-3030.
141. Vande Broek, I.; Asosingh, K.; Allegaert, V.; Leleu, X.; Facon, T.; Vanderkerken, K.; Van Camp, B.; Van Riet, I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004, 18 (5), 976-982.
142. Kehrl, J. H.; Roberts, A. B.; Wakefield, L. M.; Jakowlew, S.; Sporn, M. B.; Fauci, A. S. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 1986, 137 (12), 3855-3860.
143. Urashima, M.; Ogata, A.; Chauhan, D.; Hatziyanni, M.; Vidriales, M. B.; Dedera, D. A.; Schlossman, R. L.; Anderson, K. C. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996, 87 (5), 1928-1938.
144. Hayashi, T.; Hideshima, T.; Nguyen, A. N.; Munoz, O.; Podar, K.; Hamasaki, M.; Ishitsuka, K.; Yasui, H.; Richardson, P.; Chakravarty, S.; Murphy, A.; Chauhan, D.; Higgins, L. S.; Anderson, K. C. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 2004, 10 (22), 7540-7546.
145. Vande Broek, I.; Asosingh, K.; Vanderkerken, K.; Straetmans, N.; Van Camp, B.; Van Riet, I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Brit. J. Cancer 2003, 88 (6), 855-862.
146. Matsumoto, T.; Abe, M. TGF-beta-related mechanisms of bone destruction in multiple myeloma. Bone 2011, 48 (1), 129-134.
147. Moss, S. E.; Morgan, R. O. The annexins. Genome Biol. 2004, 5 (4), 219.
148. Bao, H.; Jiang, M.; Zhu, M.; Sheng, F.; Ruan, J.; Ruan, C. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Intern. J. Hematol. 2009, 90 (2), 177-185.
149. D'Souza, S.; Kurihara, N.; Shiozawa, Y.; Joseph, J.; Taichman, R.; Galson, D. L.; Roodman, G. D. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood 2012, 119 (8), 1888-1896.
150. Constantin, G. PSGL-1 as a novel therapeutic target. Drug News Perspect. 2004, 17 (9), 579-586.
151. Azab, A. K.; Quang, P.; Azab, F.; Pitsillides, C.; Thompson, B.; Chonghaile, T.; Patton, J. T.; Maiso, P.; Monrose, V.; Sacco, A.; Ngo, H. T.; Flores, L. M.; Lin, C. P.; Magnani, J. L.; Kung, A. L.; Letai, A.; Carrasco, R.; Roccaro, A. M.; Ghobrial, I. M. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 2012, 119 (6), 1468-1478.
152. Choi, S. J.; Cruz, J. C.; Craig, F.; Chung, H.; Devlin, R. D.; Roodman, G. D.; Alsina, M. Macrophage inflammatory protein 1- alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96 (2), 671-675.
153. Terpos, E.; Politou, M.; Szydlo, R.; Goldman, J. M.; Apperley, J. F.; Rahemtulla, A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br. J. Haematol. 2003, 123 (1), 106-109.
154. Oba, Y.; Lee, J. W.; Ehrlich, L. A.; Chung, H. Y.; Jelinek, D. F.; Callander, N. S.; Horuk, R.; Choi, S. J.; Roodman, G. D. MIP- 1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp. Hematol. 2005, 33 (3), 272-278.
155. Lacey, D. L.; Timms, E.; Tan, H. L.; Kelley, M. J.; Dunstan, C. R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; Hsu, H.; Sullivan, J.; Hawkins, N.; Davy, E.; Capparelli, C.; Eli, A.; Qian, Y. X.; Kaufman, S.; Sarosi, I.; Shalhoub, V.; Senaldi, G.; Guo, J.; Delaney, J.; Boyle, W. J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93 (2), 165-176.
156. Simonet, W. S.; Lacey, D. L.; Dunstan, C. R.; Kelley, M.; Chang, M. S.; Luthy, R.; Nguyen, H. Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; Elliott, R.; Colombero, A.; Tan, H. L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-Gegg, L.; Hughes, T. M.; Hill, D.; Pattison, W.; Campbell, P.; Sander, S.; Van, G.; Tarpley, J.; Derby, P.; Lee, R.; Boyle, W. J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89 (2), 309-319.
157. Giuliani, N.; Bataille, R.; Mancini, C.; Lazzaretti, M.; Barille, S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98 (13), 3527-3533.
158. Seidel, C.; Hjertner, O.; Abildgaard, N.; Heickendorff, L.; Hjorth, M.; Westin, J.; Nielsen, J. L.; Hjorth-Hansen, H.; Waage, A.; Sundan, A.; Borset, M. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001, 98 (7), 2269-2271.
159. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J. D., Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New Eng. J. Med. 2003, 349 (26), 2483-2494.
160. Giuliani, N.; Morandi, F.; Tagliaferri, S.; Lazzaretti, M.; Donofrio, G.; Bonomini, S.; Sala, R.; Mangoni, M.; Rizzoli, V. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007, 67 (16), 7665-7674.
161. Qiang, Y. W.; Chen, Y.; Stephens, O.; Brown, N.; Chen, B.; Epstein, J.; Barlogie, B.; Shaughnessy, J. D., Jr. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112 (1), 196-207.
162. Yaccoby, S.; Ling, W.; Zhan, F.; Walker, R.; Barlogie, B.; Shaughnessy, J. D., Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109 (5), 2106-2111.
163. Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S. A.; Shen, Z.; Patel, N.; Tai, Y. T.; Chauhan, D.; Mitsiades, C.; Prabhala, R.; Raje, N.; Anderson, K. C.; Stover, D.R.; Munshi, N. C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114 (2), 371-379.
164. Oshima, T.; Abe, M.; Asano, J.; Hara, T.; Kitazoe, K.; Sekimoto, E.; Tanaka, Y.; Shibata, H.; Hashimoto, T.; Ozaki, S.; Kido, S.; Inoue, D.; Matsumoto, T. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005, 106 (9), 3160-3165.
165. Giuliani, N.; Colla, S.; Morandi, F.; Lazzaretti, M.; Sala, R.; Bonomini, S.; Grano, M.; Colucci, S.; Svaldi, M.; Rizzoli, V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106 (7), 2472-2483.
166. Standal, T.; Seidel, C.; Hjertner, O.; Plesner, T.; Sanderson, R. D.; Waage, A.; Borset, M.; Sundan, A. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002, 100 (8), 3002-3007.
167. Sanderson, R. D.; Yang, Y.; Suva, L. J.; Kelly, T. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol. 2004, 23 (6), 341-352.
168. Cornelissen, J. J.; Sonneveld, P.; Schoester, M.; Raaijmakers, H. G.; Nieuwenhuis, H. K.; Dekker, A. W.; Lokhorst, H. M. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J. Clin. Oncol. 1994, 12 (1), 115-119.
169. Hazlehurst, L. A.; Foley, N. E.; Gleason-Guzman, M. C.; Hacker, M. P.; Cress, A. E.; Greenberger, L. W.; De Jong, M. C.; Dalton, W. S. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 1999, 59 (5), 1021-1028.
170. Damiano, J. S.; Dalton, W. S. Integrin-mediated drug resistance in multiple myeloma. Leukemia Lymphoma 2000, 38 (1-2), 71-81.
171. Fuks, Z.; Vlodavsky, I.; Andreeff, M.; McLoughlin, M.; Haimovitz-Friedman, A. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur. J. Cancer 1992, 28A (4-5), 725-731.
172. Nagata, S. Apoptosis by death factor. Cell 1997, 88 (3), 355-365.
173. Scaffidi, C.; Fulda, S.; Srinivasan, A.; Friesen, C.; Li, F.; Tomaselli, K. J.; Debatin, K. M.; Krammer, P. H.; Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO 1998, 17 (6), 1675-1687.
174. Widmann, C.; Gibson, S.; Johnson, G. L. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J. Biol. Chem. 1998, 273 (12), 7141-7147.
175. Wang, M. W.; Consoli, U.; Lane, C. M.; Durett, A.; Lauppe, M. J.; Champlin, R.; Andreeff, M.; Deisseroth, A. B. Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ. 1998, 9 (2), 105-112.
176. Hazlehurst, L. A.; Argilagos, R. F.; Dalton, W. S. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 2007, 136 (2), 269-275.
177. Hazlehurst, L. A.; Damiano, J. S.; Buyuksal, I.; Pledger, W. J.; Dalton, W. S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000, 19 (38), 4319-4327.
178. Nefedova, Y.; Cheng, P.; Alsina, M.; Dalton, W. S.; Gabrilovich, D. I. Involvement of Notch-1 signaling in bone marrow stromamediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004, 103 (9), 3503-3510.
179. Davies, F. E.; Raje, N.; Hideshima, T.; Lentzsch, S.; Young, G.; Tai, Y. T.; Lin, B.; Podar, K.; Gupta, D.; Chauhan, D.; Treon, S. P.; Richardson, P. G.; Schlossman, R. L.; Morgan, G. J.; Muller, G. W.; Stirling, D. I.; Anderson, K. C. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98 (1), 210-216.
180. Vacca, A.; Scavelli, C.; Montefusco, V.; Di Pietro, G.; Neri, A.; Mattioli, M.; Bicciato, S.; Nico, B.; Ribatti, D.; Dammacco, F.; Corradini, P. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J. Clin. Oncol. 2005, 23 (23), 5334-5346.
181. Oliveira, A. M.; Maria, D. A.; Metzger, M.; Linardi, C.; Giorgi, R. R.; Moura, F.; Martinez, G. A.; Bydlowski, S. P.; Novak, E. M. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leukemia Res. 2009, 33 (7), 970-973.
182. Segarra, M.; Lozano, E.; Corbera-Bellalta, M.; Vilardell, C.; Cibeira, M. T.; Esparza, J.; Izco, N.; Blade, J.; Cid, M. C. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrinmediated signaling pathways. Haematologica 2010, 95 (3), 456-463.
183. Breitkreutz, I.; Raab, M. S.; Vallet, S.; Hideshima, T.; Raje, N.; Mitsiades, C.; Chauhan, D.; Okawa, Y.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22 (10), 1925-1932.
184. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San-Miguel, J. F.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W. S.; Boral, A. L.; Esseltine, D. L.; Porter, J. B.; Schenkein, D.; Anderson, K. C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Eng. J. Med. 2005, 352 (24), 2487-2498.
185. Hideshima, T.; Chauhan, D.; Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dang, L.; Castro, A.; Palombella, V.; Adams, J.; Anderson, K. C. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 2002, 277 (19), 16639-16647.
186. Obeng, E. A.; Carlson, L. M.; Gutman, D. M.; Harrington, W. J., Jr.; Lee, K. P.; Boise, L. H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107 (12), 4907-4916.
187. Gu, H.; Chen, X.; Gao, G.; Dong, H. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol. Cancer Ther. 2008, 7 (8), 2298-2307.
188. Noborio-Hatano, K.; Kikuchi, J.; Takatoku, M.; Shimizu, R.; Wada, T.; Ueda, M.; Nobuyoshi, M.; Oh, I.; Sato, K.; Suzuki, T.; Ozaki, K.; Mori, M.; Nagai, T.; Muroi, K.; Kano, Y.; Furukawa, Y.; Ozawa, K. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009, 28 (2), 231-242.
189. Ko, B. S.; Chang, T. C.; Chen, C. H.; Liu, C. C.; Kuo, C. C.; Hsu, C.; Shen, Y. C.; Shen, T. L.; Golubovskaya, V. M.; Chang, C. C.; Shyue, S. K.; Liou, J. Y. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci. 2010, 86 (5-6), 199-206.
190. Michigami, T.; Shimizu, N.; Williams, P. J.; Niewolna, M.; Dallas, S. L.; Mundy, G. R.; Yoneda, T. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000, 96 (5), 1953-1960.
191. Olson, D. L.; Burkly, L. C.; Leone, D. R.; Dolinski, B. M.; Lobb, R. R. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer Ther. 2005, 4 (1), 91-99.
192. Podar, K.; Zimmerhackl, A.; Fulciniti, M.; Tonon, G.; Hainz, U.; Tai, Y. T.; Vallet, S.; Halama, N.; Jager, D.; Olson, D. L.; Sattler, M.; Chauhan, D.; Anderson, K. C. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br. J. Haematol. 2011, 155 (4), 438-448.
193. Weitz-Schmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 2001, 7 (6), 687-692.
194. Schmidmaier, R.; Mandl-Weber, S.; Gaul, L.; Baumann, P.; Bumeder, I.; Straka, C.; Emmerich, B. Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway. Int. J. Oncol. 2007, 31 (4), 969-976.
195. Wang, X.; Zhang, Z.; Yao, C. Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs. Med. Oncol. (Northwood, London, England) 2011, 28 (4), 1596-1600.
196. Cox, D.; Brennan, M.; Moran, N. Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 2010, 9 (10), 804-820.
197. Watterson, S. H.; Xiao, Z.; Dodd, D. S.; Tortolani, D. R.; Vaccaro, W.; Potin, D.; Launay, M.; Stetsko, D. K.; Skala, S.; Davis, P. M.; Lee, D.; Yang, X.; McIntyre, K. W.; Balimane, P.; Patel, K.; Yang, Z.; Marathe, P.; Kadiyala, P.; Tebben, A. J.; Sheriff, S.; Chang, C. Y.; Ziemba, T.; Zhang, H.; Chen, B. C.; DelMonte, A. J.; Aranibar, N.; McKinnon, M.; Barrish, J. C.; Suchard, S. J.; Murali Dhar, T. G. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5- dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-tria zaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521). J. Med. Chem. 2010, 53 (9), 3814-3830.
198. Hersey, P.; Sosman, J.; O'Day, S.; Richards, J.; Bedikian, A.; Gonzalez, R.; Sharfman, W.; Weber, R.; Logan, T.; Buzoianu, M.; Hammershaimb, L.; Kirkwood, J. M. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010, 116 (6), 1526-1534.
199. Delbaldo, C.; Raymond, E.; Vera, K.; Hammershaimb, L.; Kaucic, K.; Lozahic, S.; Marty, M.; Faivre, S. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest. New Drugs 2008, 26 (1), 35-43.
200. Stupp, R.; Hegi, M. E.; Neyns, B.; Goldbrunner, R.; Schlegel, U.; Clement, P. M.; Grabenbauer, G. G.; Ochsenbein, A. F.; Simon, M.; Dietrich, P. Y.; Pietsch, T.; Hicking, C.; Tonn, J. C.; Diserens, A. C.; Pica, A.; Hermisson, M.; Krueger, S.; Picard, M.; Weller, M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28 (16), 2712-2718.
201. Feagan, B. G.; Greenberg, G. R.; Wild, G.; Fedorak, R. N.; Pare, P.; McDonald, J. W.; Dube, R.; Cohen, A.; Steinhart, A. H.; Landau, S.; Aguzzi, R. A.; Fox, I. H.; Vandervoort, M. K. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New Eng. J. Med. 2005, 352 (24), 2499-2507.
202. Tai, Y. T.; Soydan, E.; Song, W.; Fulciniti, M.; Kim, K.; Hong, F.; Li, X. F.; Burger, P.; Rumizen, M. J.; Nahar, S.; Podar, K.; Hideshima, T.; Munshi, N. C.; Tonon, G.; Carrasco, R. D.; Afar, D. E.; Anderson, K. C. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009, 113 (18), 4309-4318.
203. Hsi, E. D.; Steinle, R.; Balasa, B.; Szmania, S.; Draksharapu, A.; Shum, B. P.; Huseni, M.; Powers, D.; Nanisetti, A.; Zhang, Y.; Rice, A. G.; van Abbema, A.; Wong, M.; Liu, G.; Zhan, F.; Dillon, M.; Chen, S.; Rhodes, S.; Fuh, F.; Tsurushita, N.; Kumar, S.; Vexler, V.; Shaughnessy, J. D., Jr.; Barlogie, B.; van Rhee, F.; Hussein, M.; Afar, D. E.; Williams, M. B. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 2008, 14 (9), 2775-2784.
204. Tai, Y. T.; Dillon, M.; Song, W.; Leiba, M.; Li, X. F.; Burger, P.; Lee, A. I.; Podar, K.; Hideshima, T.; Rice, A. G.; van Abbema, A.; Jesaitis, L.; Caras, I.; Law, D.; Weller, E.; Xie, W.; Richardson, P.; Munshi, N. C.; Mathiot, C.; Avet-Loiseau, H.; Afar, D. E.; Anderson, K. C. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibodydependent cellular cytotoxicity in the bone marrow milieu. Blood 2008, 112 (4), 1329-1337.
205. van Rhee, F.; Szmania, S. M.; Dillon, M.; van Abbema, A. M.; Li, X.; Stone, M. K.; Garg, T. K.; Shi, J.; Moreno-Bost, A. M.; Yun, R.; Balasa, B.; Ganguly, B.; Chao, D.; Rice, A. G.; Zhan, F.; Shaughnessy, J. D., Jr.; Barlogie, B.; Yaccoby, S.; Afar, D. E. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol. Cancer Ther. 2009, 8 (9), 2616-2624.
206. Jakubowiak, A. J.; Benson, D. M.; Bensinger, W.; Siegel, D. S.; Zimmerman, T. M.; Mohrbacher, A.; Richardson, P. G.; Afar, D. E.; Singhal, A. K.; Anderson, K. C. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J. Clin. Oncol. 2012, 30 (16), 1960-1965.
207. Riechelmann, H.; Sauter, A.; Golze, W.; Hanft, G.; Schroen, C.; Hoermann, K.; Erhardt, T.; Gronau, S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008, 44 (9), 823-829.
208. Rupp, U.; Schoendorf-Holland, E.; Eichbaum, M.; Schuetz, F.; Lauschner, I.; Schmidt, P.; Staab, A.; Hanft, G.; Huober, J.; Sinn, H. P.; Sohn, C.; Schneeweiss, A. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007, 18 (4), 477-485.
209. Greiner, J.; Li, L.; Ringhoffer, M.; Barth, T. F.; Giannopoulos, K.; Guillaume, P.; Ritter, G.; Wiesneth, M.; Dohner, H.; Schmitt, M. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005, 106 (3), 938-945.
210. Schmitt, M.; Schmitt, A.; Rojewski, M. T.; Chen, J.; Giannopoulos, K.; Fei, F.; Yu, Y.; Gotz, M.; Heyduk, M.; Ritter, G.; Speiser, D. E.; Gnjatic, S.; Guillaume, P.; Ringhoffer, M.; Schlenk, R. F.; Liebisch, P.; Bunjes, D.; Shiku, H.; Dohner, H.; Greiner, J. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008, 111 (3), 1357-1365.
211. Grignani, G.; Perissinotto, E.; Cavalloni, G.; Carnevale Schianca, F.; Aglietta, M. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. J Clin Oncol 2005, 23 (16), 3871-3872; author reply 3872-3873.
212. Liesveld, J. L.; Bechelli, J.; Rosell, K.; Lu, C.; Bridger, G.; Phillips, G., 2nd; Abboud, C. N. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leukemia Res. 2007, 31 (11), 1553-1563.
213. Li, J. K.; Yu, L.; Shen, Y.; Zhou, L. S.; Wang, Y. C.; Zhang, J. H. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J. Gastroenterol. 2008, 14 (15), 2308-2313.
214. Lili, J.; Yuchen, S.; Zhengtao, W. The chemokine SDF-1alpha suppresses fibronectin-mediated in vitro lymphocytes adhesion. Molecules and Cells 2006, 22 (3), 308-313.
215. Zannettino, A. C.; Farrugia, A. N.; Kortesidis, A.; Manavis, J.; To, L. B.; Martin, S. K.; Diamond, P.; Tamamura, H.; Lapidot, T.; Fujii, N.; Gronthos, S. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005, 65 (5), 1700-1709.
216. Beider, K.; Begin, M.; Abraham, M.; Wald, H.; Weiss, I. D.; Wald, O.; Pikarsky, E.; Zeira, E.; Eizenberg, O.; Galun, E.; Hardan, I.; Engelhard, D.; Nagler, A.; Peled, A. CXCR4 antagonist 4Fbenzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp. Hematol. 2011, 39 (3), 282-292.
217. Dhillon, S.; Lyseng-Williamson, K. A. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 2008, 68 (4), 507-534.
218. Fromigue, O.; Lagneaux, L.; Body, J. J. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res.: the official journal of the American Society for Bone and Mineral Research 2000, 15 (11), 2211-2221.
219. Lee, M. V.; Fong, E. M.; Singer, F. R.; Guenette, R. S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001, 61 (6), 2602-2608.
220. Tassone, P.; Forciniti, S.; Galea, E.; Morrone, G.; Turco, M. C.; Martinelli, V.; Tagliaferri, P.; Venuta, S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000, 14 (5), 841-844.
221. Shipman, C. M.; Rogers, M. J.; Apperley, J. F.; Russell, R. G.; Croucher, P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. 1997, 98 (3), 665-672.
222. Hughes, D. E.; Wright, K. R.; Uy, H. L.; Sasaki, A.; Yoneda, T.; Roodman, G. D.; Mundy, G. R.; Boyce, B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res.: the official journal of the American Society for Bone and Mineral Research 1995, 10 (10), 1478-1487.
223. Selander, K. S.; Monkkonen, J.; Karhukorpi, E. K.; Harkonen, P.; Hannuniemi, R.; Vaananen, H. K. Characteristics of clodronateinduced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 1996, 50 (5), 1127-1138.
224. Corso, A.; Ferretti, E.; Lunghi, M.; Zappasodi, P.; Mangiacavalli, S.; De Amici, M.; Rusconi, C.; Varettoni, M.; Lazzarino, M. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005, 104 (1), 118-125.
225. Moschetta, M.; Di Pietro, G.; Ria, R.; Gnoni, A.; Mangialardi, G.; Guarini, A.; Ditonno, P.; Musto, P.; D'Auria, F.; Ricciardi, M. R.; Dammacco, F.; Ribatti, D.; Vacca, A. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur. J. Cancer 2010, 46 (2), 420-429.
226. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Lutz, R. J.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Vallet, S.; Pozzi, S.; Santo, L.; Perrone, G.; Tai, Y. T.; Cirstea, D.; Raje, N. S.; Uherek, C.; Dalken, B.; Aigner, S.; Osterroth, F.; Munshi, N.; Richardson, P.; Anderson, K. C. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 2009, 15 (12), 4028-4037.
227. Clezardin, P. The antitumor potential of bisphosphonates. Semin. Oncol. 2002, 29 (6 Suppl 21), 33-42.
228. Morgan, G. J.; Child, J. A.; Gregory, W. M.; Szubert, A. J.; Cocks, K.; Bell, S. E.; Navarro-Coy, N.; Drayson, M. T.; Owen, R. G.; Feyler, S.; Ashcroft, A. J.; Ross, F. M.; Byrne, J.; Roddie, H.; Rudin, C.; Cook, G.; Jackson, G. H.; Wu, P.; Davies, F. E. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011, 12 (8), 743-752.
229. Palmer, K. J.; Goa, K. L. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993, 45 (2), 259-294.
230. Falanga, A.; Vignoli, A.; Marchetti, M.; Barbui, T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003, 17 (8), 1636-1642.
231. Koehl, G. E.; Geissler, E. K.; Iacobelli, M.; Frei, C.; Burger, V.; Haffner, S.; Holler, E.; Andreesen, R.; Schlitt, H. J.; Eissner, G. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol. Ther. 2007, 6 (5), 686-690.
232. Mitsiades, C. S.; Rouleau, C.; Echart, C.; Menon, K.; Teicher, B.; Distaso, M.; Palumbo, A.; Boccadoro, M.; Anderson, K. C.; Iacobelli, M.; Richardson, P. G. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin. Cancer Res. 2009, 15 (4), 1210-1221.
233. Palumbo, A.; Larocca, A.; Genuardi, M.; Kotwica, K.; Gay, F.; Rossi, D.; Benevolo, G.; Magarotto, V.; Cavallo, F.; Bringhen, S.; Rus, C.; Masini, L.; Iacobelli, M.; Gaidano, G.; Mitsiades, C.; Anderson, K.; Boccadoro, M.; Richardson, P. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica 2010, 95 (7), 1144-1149.
234. Tassone, P.; Goldmacher, V. S.; Neri, P.; Gozzini, A.; Shammas, M. A.; Whiteman, K. R.; Hylander-Gans, L. L.; Carrasco, D. R.; Hideshima, T.; Shringarpure, R.; Shi, J.; Allam, C. K.; Wijdenes, J.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004, 104 (12), 3688-3696.